- Home
- THFF vs ANAB Comparison
THFF vs ANAB Comparison
Compare THFF & ANAB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- THFF
- ANAB
- Stock Information
- Founded
- THFF 1984
- ANAB 2005
- Country
- THFF United States
- ANAB United States
- Employees
- THFF N/A
- ANAB N/A
- Industry
- THFF Major Banks
- ANAB Biotechnology: Pharmaceutical Preparations
- Sector
- THFF Finance
- ANAB Health Care
- Exchange
- THFF Nasdaq
- ANAB Nasdaq
- Market Cap
- THFF 589.0M
- ANAB 600.4M
- IPO Year
- THFF N/A
- ANAB 2017
- Fundamental
- Price
- THFF $48.92
- ANAB $21.17
- Analyst Decision
- THFF Hold
- ANAB Buy
- Analyst Count
- THFF 1
- ANAB 11
- Target Price
- THFF $45.00
- ANAB $54.64
- AVG Volume (30 Days)
- THFF 68.3K
- ANAB 636.7K
- Earning Date
- THFF 10-22-2024
- ANAB 11-05-2024
- Dividend Yield
- THFF 3.68%
- ANAB N/A
- EPS Growth
- THFF N/A
- ANAB N/A
- EPS
- THFF 3.68
- ANAB N/A
- Revenue
- THFF $190,119,000.00
- ANAB $57,172,000.00
- Revenue This Year
- THFF N/A
- ANAB $207.49
- Revenue Next Year
- THFF $12.01
- ANAB N/A
- P/E Ratio
- THFF $13.30
- ANAB N/A
- Revenue Growth
- THFF N/A
- ANAB 282.17
- 52 Week Low
- THFF $34.58
- ANAB $13.36
- 52 Week High
- THFF $50.63
- ANAB $41.31
- Technical
- Relative Strength Index (RSI)
- THFF 62.21
- ANAB 37.43
- Support Level
- THFF $47.37
- ANAB $18.03
- Resistance Level
- THFF $50.25
- ANAB $22.94
- Average True Range (ATR)
- THFF 1.32
- ANAB 1.39
- MACD
- THFF 0.02
- ANAB 0.26
- Stochastic Oscillator
- THFF 79.76
- ANAB 63.82
About THFF First Financial Corporation Indiana
First Financial Corp operates as a financial holding company, which is engaged in the provision of financial services in the United States. The company offers a wide variety of financial services including commercial, mortgage, and consumer lending, lease financing, trust account services, depositor services, and insurance services, through its subsidiaries. Its primary source of revenue is derived from loans to customers and investment activities.
About ANAB AnaptysBio Inc.
AnaptysBio Inc is a clinical-stage biotechnology company. The company is focused on developing antibody product candidates for unmet medical needs in inflammation and immuno-oncology. The company is developing immune cell modulating antibodies, including two wholly owned checkpoint agonists in clinical-stage development, for autoimmune and inflammatory diseases; rosnilimab, our PD-1 agonist in a Phase 2b trial for the treatment of moderate-to-severe rheumatoid arthritis (RA) and a Phase 2 trial for the treatment of moderate-to-severe ulcerative colitis (UC); and ANB032, our BTLA agonist, in a Phase 2b trial for the treatment of moderate-to-severe atopic dermatitis (AD).